Login / Signup

Treatment of dedifferentiated chordoma: a retrospective study from a large volume cancer center.

Ryan N NachwalterRobert J RothrockEvangelina KatsoulakisMrinal M GounderPatrick J BolandMark H BilskyIlya LauferAdam M SchmittYoshiya YamadaDaniel S Higginson
Published in: Journal of neuro-oncology (2019)
DC patients exhibit significantly higher rates of both synchronous and metachronous metastases, as well as shorter overall survival rates compared to conventional chordoma. The relatively poor survival outcomes with conventional therapies indicate the need to study targeted therapies for the treatment of DC.
Keyphrases
  • end stage renal disease
  • dendritic cells
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • immune response
  • young adults